J591 humanized monoclonal antibody: Phase I

Interim results from 2 U.S. Phase I trials of J591 labeled with either 177-Lutetium or 90-Yttrium in 26 patients with metastatic disease who had failed hormone therapy and chemotherapy showed that bot...